EDG-7500 Drug Asset Due Diligence Report 2026

This EDG-7500 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether EDG-7500 can convert its Small molecule drug profile and Cardiac myosin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	EDG-7500 (query alias: EDG-7500)
Modality / target	Small molecule drug; Cardiac myosin; Cardiac myosin modulators
Highest global status	Phase 2
Originator	Edgewise Therapeutics, Inc.
Active developers	Edgewise Therapeutics, Inc.

The MCP disease footprint includes Cardiomyopathy, Hypertrophic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07456059	Phase 1	Completed	24	Primary endpoint not disclosed in English source
NCT07324616	Phase 1	Completed	25	Primary endpoint not disclosed in English source
NCT07034768	Phase 1	Completed	37	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

Phase 2; n=20; evaluation: Positive. Reported fields: AE(Atrial fibrillation or atrial flutter during continuous active monitoring) = 0 times ; AE(Atrial fibrillation or atrial flutter during continuous active monitoring) = 0 times

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: LVOT-G(resting) = -71 % ; KCCQ = +17 Point

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: LVOT-G(resting; 100 and 200 mg) = - 67 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

EDG-7500 addresses Cardiomyopathy, Hypertrophic. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 12 matched transaction record(s) under the scope “target-level comparable: Cardiac myosin.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: Cardiac myosin records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-09-05	HENGRUI PHARMA Grants Braveheart Bio Commercialization Rights for HRS-1893	Phase 3	US$75.0M upfront; US$1,013.0M milestones
2024-12-20	CORXEL and Sanofi Announce an Agreement for Aficamten in Greater China Markets	NDA/BLA	Financial terms not disclosed
2024-11-19	Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan	NDA/BLA	US$52.9M upfront; US$580.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO